Vol. 3 No. 3 (2023)
Reimbursement Recommendations

Olaparib (Lynparza)

decorative image

Published March 20, 2023

Key Messages

  • CADTH recommends that Lynparza be reimbursed by public drug plans for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy if certain conditions are met.
  • Lynparza should only be covered in patients with a confirmed type of inherited (germline) abnormal BRCA gene, whose early-stage breast cancer tests negative for the HER2 protein, who are at high risk for breast cancer recurrence, and who have received chemotherapy before or after surgery.
  • Lynparza should only be reimbursed if prescribed by clinicians with expertise and experience in treating breast cancer, and if the cost is reduced.